#1OF 25
↗- Headquarters
- Cambridge, United KingdomSource: RevenueBaseRetrieved October 13, 2026
- Employee range
- 51 to 200Source: RevenueBaseRetrieved October 13, 2026
- Published list appearances
- 5 supported appearances ↗Source: RevenueBase lists
What does Artios do?
Artios uses its DcoDeR platform and expertise in DNA damage biology and drug discovery to discover and develop medicines targeting DNA damage response pathways. Its pipeline targets solid tumour indications and includes ATR inhibitor ART0380 and Polθ inhibitor ART6043 for monotherapy and combination treatment.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Company lists.
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
#1OF 25
↗#2OF 24
↗#3OF 25
↗#3OF 25
↗Positions describe ordering within each source list. See how lists are built ↗
Share your recognition
Embeddable award for your website
BADGE PREVIEW
Open the published source list.
Open the published source list.Company information
Sources & data notes.
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 18, 2026, September 19, 2026 and September 21, 2026. How the company lists are built.
Help keep this profile accurate
Something changed?
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Find your next account
Explore company profiles →One company is just the start.
Explore more companies by name, headquarters and business focus.